INmune End Period Cash Flow from 2010 to 2024
| INMB Stock | USD 11.84 0.07 0.59% |
End Period Cash Flow | First Reported 2017-03-31 | Previous Quarter 41.8 M | Current Value 35.8 M | Quarterly Volatility 26.9 M |
Check INmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among INmune main balance sheet or income statement drivers, such as Interest Expense of 1.6 M, Selling General Administrative of 6.4 M or Total Revenue of 147.2 K, as well as many exotic indicators such as Price To Sales Ratio of 1.2 K, Dividend Yield of 0.0 or PTB Ratio of 5.57. INmune financial statements analysis is a perfect complement when working with INmune Bio Valuation or Volatility modules.
INmune | End Period Cash Flow |
Latest INmune Bio's End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of INmune Bio over the last few years. It is INmune Bio's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in INmune Bio's overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
INmune End Period Cash Flow Regression Statistics
| Arithmetic Mean | 14,479,420 | |
| Geometric Mean | 517,893 | |
| Coefficient Of Variation | 160.38 | |
| Mean Deviation | 18,137,175 | |
| Median | 186,204 | |
| Standard Deviation | 23,221,590 | |
| Sample Variance | 539.2T | |
| Range | 74.8M | |
| R-Value | 0.70 | |
| Mean Square Error | 294.8T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 3,643,731 | |
| Total Sum of Squares | 7549.4T |
INmune End Period Cash Flow History
About INmune Bio Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include INmune Bio income statement, its balance sheet, and the statement of cash flows. INmune Bio investors use historical funamental indicators, such as INmune Bio's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although INmune Bio investors may use each financial statement separately, they are all related. The changes in INmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on INmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on INmune Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in INmune Bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 35.8 M | 23.6 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards INmune Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, INmune Bio's short interest history, or implied volatility extrapolated from INmune Bio options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of INmune Bio Correlation against competitors. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.